Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.630
+0.030 (0.83%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or 39.69% compared to the previous year. That makes Prelude Therapeutics the 32,886th largest employer in the world and 4,286th in the United States.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$283,848
Profits / Employee
-$765,671
Market Cap
373.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Capricor Therapeutics | 231 |
| Kyverna Therapeutics | 149 |
| Enanta Pharmaceuticals | 120 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Scribe Therapeutics | 82 |
| Rezolute | 58 |
| Fennec Pharmaceuticals | 35 |
PRLD News
- 5 days ago - Prelude Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 9 days ago - Prelude Therapeutics to Participate in the Chardan Healthcare Conference - GlobeNewsWire
- 12 days ago - H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly - TheFly
- 12 days ago - Prelude enters clinical trial collaboration, supply agreement with Eli Lilly - TheFly
- 12 days ago - Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer - GlobeNewsWire
- 5 weeks ago - Prelude Therapeutics initiated with an Overweight at JPMorgan - TheFly
- 5 weeks ago - Prelude Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire